This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

AMRI Hires Senior Manager To Oversee Facilities At Burlington Aseptic Fill Operations

ALBANY, N.Y., March 27, 2012 /PRNewswire/ -- AMRI (NASDAQ: AMRI) announced today another key addition to its management team at its aseptic fill and finish facility in Burlington, Mass. Stephen Rossmeisl has joined the company as Senior Facilities Manager, reporting to Eric Peterson, Director of Manufacturing. Mr. Rossmeisl's more than 15 years of plant engineering and facilities management experience will provide the expertise and leadership necessary to effectively plan and implement facility maintenance programs, environmental monitoring compliance systems and expansion projects.

(Logo: http://photos.prnewswire.com/prnh/20120229/NY61160LOGO)

Combined with previously announced recent senior leadership changes at Burlington, Mr. Rossmeisl's addition further demonstrates AMRI's commitment to providing industry leading aseptic services with uncompromising quality to the company's growing client base.  

AMRI's Burlington, Mass. facility offers clients innovative aseptic formulation and filling services for pre-clinical through small-volume, commercial-scale production of liquid-filled parenterals, biologics and medical devices in vials, syringes and other custom containers.

Mr. Rossmeisl has worked for large pharmaceutical companies performing all phases of construction, design, and commissioning. He comes to AMRI from his most recent role as the Associate Director of Facilities Operations for Shire HGT in Lexington, Mass., where in addition to maintenance oversight he served as the lead project engineer for significant laboratory and office expansion projects. Mr. Rossmeisl's experience with critical cleanroom equipment, utilities and systems will strengthen AMRI's ability to meet the growing needs of its customers as the level of activity of new business at Burlington continues on a path to a return to previously robust levels.

"Steve brings extensive knowledge and experience in supporting critical cleanroom infrastructure, equipment and GMP operations," said Steven R. Hagen, Ph.D., Vice President, Pharmaceutical Development and Manufacturing, AMRI. "Steve will be instrumental in ensuring compliance and overall effectiveness of the facility's preventive maintenance program and critical environmental monitoring systems, and will lead the planning, oversight and execution of future expansion projects."

About AMRI

Albany Molecular Research, Inc. (AMRI) is a global contract research and manufacturing organization with more than twenty years experience providing customers fully integrated drug discovery, development, and manufacturing services. AMRI supplies a broad range of services and technologies that support the discovery and development of pharmaceutical products and the manufacturing of API and drug product for existing and experimental new drugs. With locations in the United States, Europe, and Asia, AMRI maintains geographic proximity and flexible cost models. AMRI has also historically leveraged its drug-discovery expertise to execute on several internal drug discovery programs, which have progressed to the development candidate stage and in some cases into Phase I clinical development. AMRI has successfully partnered certain programs and is actively seeking to out-license its remaining programs to strategic partners for further development.

SOURCE AMRI

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,098.45 +18.88 0.11%
S&P 500 2,003.37 +6.63 0.33%
NASDAQ 4,580.2710 +22.5760 0.50%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs